Response from AHZ, page-20

What will save us poor share holders is the success of TAVR.

1) Success of the animal Trial. (we should know soon)
2) Partnership with one of the majors.
3) the long overdue approvals to sell in Australia and Europe.
4) get into the Chinese market which is potentially bigger than all the other markets we sell to currently, I suspect this is one of the
reasons Bright Star are now one of our corner stone investors.

1, 2 and hopefully 3 will potentially be decided this quarter.

if successful. what effect will that have on the SP if we receive a large sum of money from a TAVR deal?

To get the above done, the company had to hire highly paid individuals, this included the advisory board which caused the money burn that got us to where we are now and hopefully the TAVR project will be our saviour.

From what we have been told the project is progressing successfully so far.

as for the high outgoings for this quarter $15.5 Million, my guess is it's a one off to get rid of the infusion business which will be offset by the sale
price of the business and R&D refund for this year that could potentially reduce the money burn.

I continue to hold, hopeful that this painful period will be a memory from the past soon. 

all the best